by increasing the antiviral effect
Long lasting continuation of a “suppressive”therapy
Combinations with PEG-INF, ribavirin & amantadine
Protease inhibitors
Immunomodulatory treatments (IL-2, -10, -12,
vaccine therapy)
by modifying the equilibrium between fibrogenesis and fibrolysis
Traitement des hépatites virales C
Inconvénients: non réponse
| Diapositive précédente | Diapositive suivante | Revenir à la première diapositive | Afficher la version graphique |